VECT earnings

- Transaction Advances Ironwood's Vision of Becoming the Leading GI Healthcare Company - - Adds apraglutide, Next Generation, Synthetic GLP-2 Analog in Phase 3 for Short Bowel Syndrome with Intestinal Failure (SBS-IF); Potential to become Best-in-Class for SBS-IF - - Orphan Drug Designation Received for Treatment of Adult Patients with SBS-IF; Topline Results of Phase 3 Trial Expected by the End of 2023 - - Ironwood to Commence All-Cash Tender Offer to Acquire All Outstanding Shares of VectivBio for $17.00 per Share - - Ironwood to Host Conference Call and Webcast Today at 8:30 a.m. ET - Ironwood Pharmaceuticals, Inc. ("Ironwood") (NASDAQ:IRWD), a GI-focused healthcare company, an

BASEL, Switzerland, April 12, 2023 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today announced they will report financial results for the full year ended December 31, 2022 and provide a business update on Wednesday, April 19, 2023 at 8:00 a.m. ET. A live webcast will be accessible under ‘Events & Presentations' in the ‘Investors & Media' section of VectivBio's website at ir.vectivbio.com. An archived replay of the webcast will be available on VectivBio's website approximately two hours after the conference call and will be available for thirty days

BASEL, Switzerland, Oct. 12, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-stage biopharmaceutical company pioneering novel transformational treatments for severe rare conditions, today published the date of the Extraordinary General Meeting, which will be held on Friday, December 9, 2022, at 10:00 a.m. CEST / 4:00 a.m. EDT at the offices of VectivBio Holding AG at Aeschenvorstadt 36, 4051 Basel, Switzerland. The sole agenda item of the Extraordinary General Meeting will be the election of Wouter Joustra as a new member of the Board of Directors. In view of the ongoing COVID-19 pandemic, and in accordance with the Ordinance 3 of the Swiss Federal C

$5 Million of Non-Dilutive FinancingVeteran Biotech Executive Appointed to Board KANSAS CITY, Kan., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ:CING), a clinical-stage biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the quarter ended June 30, 2022, and provided a clinical and business update. Highlights include the announcement of $5 million of debt financing and the appointment of an additional member to Cingulate's Board of Directors. "Cingulate continues to advance its mission in bringin

Exclusive License with Asahi Kasei Pharma to develop and commercialize Apraglutide in Japan includes $30 million upfront cash payment, eligibility for up to $170 million in development and commercial milestones and double-digit royalties on apraglutide sales in JapanLoan facility established with Kreos Capital, a leading global growth lender to life sciences and healthcare companies, granting the company access of up to $75 million, with a minimum commitment to draw down $10 millionVectivBio to hold FY 2021 Earnings Call and Business Update on April 7, 2022, at 8:00 a.m. ET BASEL, Switzerland, March 30, 2022 (GLOBE NEWSWIRE) -- VectivBio Holding AG ("VectivBio") (NASDAQ:VECT), a clinical-